Heparin-induced thrombocytopenia.
Each year, 25% of all hospitalized patients are affected by venous thromboembolism, a disease comprising deep vein thrombosis and pulmonary embolism, that is responsible for up to 10% of all inpatient deaths (Alikhan, Peters, Wilmott, Cohen, 2004). Used in both the treatment and the prevention of venous thromboembolism, heparin is administered to more than 12 million patients each year in the United States, making it one of the most widely prescribed medications and the leading intravenous anticoagulant. Heparin-induced thrombocytopenia is an antibody-mediated adverse drug reaction to heparin therapy with potentially life-threatening complications. This article discusses the pathogenesis, diagnosis, and treatment of patients with heparin-induced thrombocytopenia.
Unkle
David W
DW
Acute/Critical Care Nurse Practitioner Program, School of Nursing, University of Medicine & Dentistry of New Jersey, Stratford, NJ, USA.
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D016903:Drug Monitoring; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D019934:International Normalized Ratio; D015985:Precipitating Factors; D011517:Prothrombin Time; D011655:Pulmonary Embolism / Q000188:drug therapy; D013917:Thrombin / Q000037:antagonists & inhibitors; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D014481:United States / Q000453:epidemiology; D054556:Venous Thromboembolism / Q000188:drug therapy; D014812:Vitamin K / Q000627:therapeutic use
D000925:Anticoagulants; D014812:Vitamin K; D006493:Heparin; D013917:Thrombin